• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于严重急性呼吸综合征冠状病毒2感染后急性后遗症的抗组胺药

Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection.

作者信息

Pinto Melissa D, Lambert Natalie, Downs Charles A, Abrahim Heather, Hughes Thomas D, Rahmani Amir M, Burton Candace W, Chakraborty Rana

出版信息

J Nurse Pract. 2022 Mar;18(3):335-338. doi: 10.1016/j.nurpra.2021.12.016. Epub 2022 Feb 7.

DOI:10.1016/j.nurpra.2021.12.016
PMID:35153633
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8820139/
Abstract

Postacute sequelae of SARS-CoV2 (PASC) infection is an emerging global health crisis, variably affecting millions worldwide. PASC has no established treatment. We describe 2 cases of PASC in response to opportune administration of over-the-counter antihistamines, with significant improvement in symptoms and ability to perform activities of daily living. Future studies are warranted to understand the potential role of histamine in the pathogenesis of PASC and explore the clinical benefits of antihistamines in the treatment of PASC.

摘要

新型冠状病毒2型（SARS-CoV2）感染的急性后遗症（PASC）是一场正在出现的全球健康危机，在全球范围内不同程度地影响着数百万人。PASC尚无既定的治疗方法。我们描述了2例PASC患者，通过适时使用非处方抗组胺药，症状得到显著改善，日常生活活动能力也有所提高。有必要开展进一步研究，以了解组胺在PASC发病机制中的潜在作用，并探索抗组胺药在治疗PASC方面的临床益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57e0/8820139/ace02fe5b675/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57e0/8820139/2d8001f024b4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57e0/8820139/d4ce221a8502/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57e0/8820139/87834e3eab8c/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57e0/8820139/95abd79cdc39/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57e0/8820139/ace02fe5b675/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57e0/8820139/2d8001f024b4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57e0/8820139/d4ce221a8502/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57e0/8820139/87834e3eab8c/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57e0/8820139/95abd79cdc39/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57e0/8820139/ace02fe5b675/gr5_lrg.jpg

相似文献

1
Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection.用于严重急性呼吸综合征冠状病毒2感染后急性后遗症的抗组胺药
J Nurse Pract. 2022 Mar;18(3):335-338. doi: 10.1016/j.nurpra.2021.12.016. Epub 2022 Feb 7.
2
Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection.开发 SARS-CoV-2 感染后后遗症的定义。
JAMA. 2023 Jun 13;329(22):1934-1946. doi: 10.1001/jama.2023.8823.
3
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.尼马瑞韦/利托那韦片和成年人 SARS-CoV-2 感染后后遗症症状：STOP-PASC 随机临床试验。
JAMA Intern Med. 2024 Sep 1;184(9):1024-1034. doi: 10.1001/jamainternmed.2024.2007.
4
A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.SARS-CoV-2 生物库的纵向研究，用于 COVID-19 幸存者，包括有无急性后期后遗症。
BMC Infect Dis. 2021 Jul 13;21(1):677. doi: 10.1186/s12879-021-06359-2.
5
Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.严重急性呼吸综合征冠状病毒 2 感染的急性后期后遗症。
Infect Dis Clin North Am. 2022 Jun;36(2):379-395. doi: 10.1016/j.idc.2022.02.004. Epub 2022 Feb 15.
6
Association of COVID-19 Vaccination With Risk of Medically Attended Postacute Sequelae of COVID-19 During the Ancestral, Alpha, Delta, and Omicron Variant Eras.在原始毒株、阿尔法毒株、德尔塔毒株和奥密克戎毒株流行时期，新冠疫苗接种与新冠病毒感染后医学就诊的后遗症风险的关联
Open Forum Infect Dis. 2024 Aug 28;11(9):ofae495. doi: 10.1093/ofid/ofae495. eCollection 2024 Sep.
7
Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach.新冠后遗症（PASC 或长期新冠）：基于证据的方法。
Open Forum Infect Dis. 2024 Aug 27;11(9):ofae462. doi: 10.1093/ofid/ofae462. eCollection 2024 Sep.
8
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection.新冠病毒感染住院患者及新冠病毒感染后急性后遗症患者神经病理发生的血浆生物标志物
Neurol Neuroimmunol Neuroinflamm. 2022 Mar 7;9(3). doi: 10.1212/NXI.0000000000001151. Print 2022 May.
9
Dysregulated platelet function in patients with postacute sequelae of COVID-19.COVID-19 后后遗症患者血小板功能失调。
Vasc Med. 2024 Apr;29(2):125-134. doi: 10.1177/1358863X231224383. Epub 2024 Feb 9.
10
Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection.报告 SARS-CoV-2 感染后神经系统急性后遗症的人群中神经损伤和炎症的血浆标志物。
Neurol Neuroimmunol Neuroinflamm. 2022 Jun 14;9(5). doi: 10.1212/NXI.0000000000200003. Print 2022 Sep.

引用本文的文献

1
Understanding Post-COVID-19: Mechanisms, Neurological Complications, Current Treatments, and Emerging Therapies.了解新冠后状况：机制、神经并发症、当前治疗方法及新兴疗法
Int J Gen Med. 2024 Dec 17;17:6303-6321. doi: 10.2147/IJGM.S499905. eCollection 2024.
2
Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach.新冠后遗症（PASC 或长期新冠）：基于证据的方法。
Open Forum Infect Dis. 2024 Aug 27;11(9):ofae462. doi: 10.1093/ofid/ofae462. eCollection 2024 Sep.
3
Identification of HRH1 as an alternative receptor for SARS-CoV-2: insights from viral inhibition by repurposable antihistamines.

本文引用的文献

1
The other COVID-19 survivors: Timing, duration, and health impact of post-acute sequelae of SARS-CoV-2 infection.其他 COVID-19 幸存者：SARS-CoV-2 感染后急性后遗症的发生时间、持续时间和健康影响。
J Clin Nurs. 2024 Jan;33(1):76-88. doi: 10.1111/jocn.16541. Epub 2022 Sep 30.
2
COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler Looking for Clarity in the Haze of the Pandemic.COVID 症状、症状群及成为“长新冠”的预测因素——在大流行的迷雾中寻找清晰。
Clin Nurs Res. 2022 Nov;31(8):1390-1398. doi: 10.1177/10547738221125632. Epub 2022 Sep 24.
3
Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection.
鉴定 HRH1 为 SARS-CoV-2 的替代受体：抗组胺药再利用抑制病毒带来的启示。
mBio. 2024 Aug 14;15(8):e0169724. doi: 10.1128/mbio.01697-24. Epub 2024 Jul 22.
4
The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2.组胺受体 H1 可作为 SARS-CoV-2 的替代受体。
mBio. 2024 Aug 14;15(8):e0108824. doi: 10.1128/mbio.01088-24. Epub 2024 Jul 2.
5
From Acute Infection to Prolonged Health Consequences: Understanding Health Disparities and Economic Implications in Long COVID Worldwide.从急性感染到长期健康后果：了解全球长新冠的健康差异和经济影响。
Int J Environ Res Public Health. 2024 Mar 11;21(3):325. doi: 10.3390/ijerph21030325.
6
Microvascular Capillary and Precapillary Cardiovascular Disturbances Strongly Interact to Severely Affect Tissue Perfusion and Mitochondrial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Evolving from the Post COVID-19 Syndrome.微血管毛细血管和前毛细血管心血管障碍强烈相互作用，严重影响从新冠后综合征演变而来的肌痛性脑脊髓炎/慢性疲劳综合征中的组织灌注和线粒体功能。
Medicina (Kaunas). 2024 Jan 23;60(2):194. doi: 10.3390/medicina60020194.
7
Combination of H1 and H2 Histamine Receptor Antagonists: Current Knowledge and Perspectives of a Classic Treatment Strategy.H1和H2组胺受体拮抗剂的联合应用：经典治疗策略的当前认知与展望
Life (Basel). 2024 Jan 23;14(2):164. doi: 10.3390/life14020164.
8
Postacute Sequelae of SARS-CoV-2 in Children.儿童新型冠状病毒 SARS-CoV-2 的后遗症。
Pediatrics. 2024 Mar 1;153(3). doi: 10.1542/peds.2023-062570.
9
Predictive models of long COVID.长新冠预测模型。
EBioMedicine. 2023 Oct;96:104777. doi: 10.1016/j.ebiom.2023.104777. Epub 2023 Sep 4.
10
Recent Advancements on Long COVID in China: A Narrative Review.中国长期新冠的最新进展：一篇叙述性综述
Int J Gen Med. 2023 Jun 19;16:2585-2593. doi: 10.2147/IJGM.S417692. eCollection 2023.
新冠病毒感染后 15 个月，COVID-19 后急性后遗症（PASC）中 CD16+ 单核细胞中 SARS-CoV-2 S1 蛋白持续存在。
Front Immunol. 2022 Jan 10;12:746021. doi: 10.3389/fimmu.2021.746021. eCollection 2021.
4
How an effective response to post-acute sequelae of SARS-CoV-2 infection (PASC) relies on nursing research.对严重急性呼吸综合征冠状病毒2感染后遗症（PASC）的有效应对如何依赖于护理研究。
Res Nurs Health. 2021 Oct;44(5):743-745. doi: 10.1002/nur.22176. Epub 2021 Aug 8.
5
Characterizing long COVID in an international cohort: 7 months of symptoms and their impact.在一个国际队列中对长期新冠进行特征描述：7个月的症状及其影响。
EClinicalMedicine. 2021 Aug;38:101019. doi: 10.1016/j.eclinm.2021.101019. Epub 2021 Jul 15.
6
Health Care Utilization and Clinical Characteristics of Nonhospitalized Adults in an Integrated Health Care System 28-180 Days After COVID-19 Diagnosis - Georgia, May 2020-March 2021.2020 年 5 月至 2021 年 3 月，乔治亚州在新冠病毒感染后 28-180 天内，非住院成年人在综合医疗保健系统中的医疗利用情况和临床特征。
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):644-650. doi: 10.15585/mmwr.mm7017e3.
7
COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.新型冠状病毒肺炎：法莫替丁、组胺、肥大细胞及作用机制
Front Pharmacol. 2021 Mar 23;12:633680. doi: 10.3389/fphar.2021.633680. eCollection 2021.
8
Post-acute COVID-19 syndrome.新冠病毒感染后长期综合征。
Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22.
9
Long-haul COVID: heed the lessons from other infection-triggered illnesses.新冠长期症状：汲取其他感染引发疾病的教训。
Lancet. 2021 Mar 13;397(10278):967-968. doi: 10.1016/S0140-6736(21)00446-3. Epub 2021 Mar 5.
10
Sequelae in Adults at 6 Months After COVID-19 Infection.COVID-19 感染 6 个月后成年人的后遗症。
JAMA Netw Open. 2021 Feb 1;4(2):e210830. doi: 10.1001/jamanetworkopen.2021.0830.